StockMarketWire.com - Pharmaceutical and consumer strategic marketing group Cello's revenue rose 5.4% to £165.3m in the year to the end of December.

Gross profit increased by 7.1% to £92.7m (2015: £86.5m) with like-for-like gross profit growth of 5.9%.

Headline profit before tax eose by 0.8% to £10.2m (2015: £10.1m) while headline basic earnings per share were flat at 8.66p (2015: 8.72p) Other highlights:

- Statutory basic loss per share 3.23p (2015: earnings of 3.54p)

- Net debt of £5.1m (2015: £4.2m)

- Full Year dividend up 18.9% to 3.40p (2015: 2.86p)

Chief executive Mark Scott said: "Cello Health is now in a strong position to accelerate its global growth, with a particular focus on the US market.

"Cello Signal is making steady progress against its goals, with the Pulsar social media product continuing to grow strongly, as well as increasingly supporting the digital communications capability of Cello Health."






Story provided by StockMarketWire.com